CryoPort, Inc. (NASDAQ:CYRX – Get Free Report) Director Daniel Hancock sold 74,379 shares of the firm’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $20.21, for a total transaction of $1,503,199.59. Following the completion of the sale, the director owned 69,052 shares of the company’s stock, valued at $1,395,540.92. The trade was a 51.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
CryoPort Stock Down 2.2%
CYRX traded down $0.46 during midday trading on Thursday, hitting $20.10. The company had a trading volume of 659,177 shares, compared to its average volume of 664,215. CryoPort, Inc. has a 52 week low of $7.61 and a 52 week high of $21.78. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -20.72 and a beta of 1.89. The stock’s 50 day moving average price is $17.26 and its 200 day moving average price is $13.61.
CryoPort (NASDAQ:CYRX – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $50.22 million for the quarter, compared to analyst estimates of $48.66 million. CryoPort had a negative net margin of 21.46% and a negative return on equity of 8.28%. Research analysts predict that CryoPort, Inc. will post -0.88 EPS for the current year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on CYRX. KeyCorp boosted their target price on CryoPort from $17.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 6th. BTIG Research increased their price target on CryoPort from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Piper Sandler raised CryoPort to a “buy” rating in a research note on Tuesday, October 13th. Guggenheim boosted their price objective on CryoPort from $16.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Finally, Weiss Ratings raised CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, October 8th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, CryoPort currently has an average rating of “Moderate Buy” and an average price target of $21.69.
Get Our Latest Stock Analysis on CYRX
About CryoPort
Cryoport, Inc. provides temperature-controlled supply chain services for the life sciences industry. Its offerings support the development and commercial distribution of cell and gene therapies, biologics, reproductive medicine products and other temperature-sensitive materials. The company’s services include specialized shipping systems and packaging, transportation management, cryogenic storage, shipment monitoring and logistics support. These solutions are designed to help customers maintain required conditions and manage the handling of sensitive materials across clinical and commercial supply chains.
Further Reading
- Five stocks we like better than CryoPort
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.
